AI
KPTI icon

Atom Investors’s Karyopharm Therapeutics KPTI Stock Holding History

Atom Investors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,322
Closed -$176K – 580
2024
Q4 		$176K Hold
17,322
– – 0.02% 425
2024
Q3 		$216K Sell
17,322
-134
-0.8% -$1.67K 0.02% 409
2024
Q2 		$227K Buy
17,456
+1,163
+7% +$19.3K 0.02% 412
2024
Q1 		$369K Buy
16,293
+1,847
+13% +$32.4K 0.05% 380
2023
Q4 		$187K Buy
14,446
+1,724
+14% +$23.2K 0.03% 410
2023
Q3 		$256K Buy
12,722
+414
+3% +$9.29K 0.06% 341
2023
Q2 		$330K Buy
+12,308
New +$530K 0.13% 177
2020
Q3 		– Sell
-25,987
Closed -$7.38M – 563
2020
Q2 		$7.38M Sell
25,987
-5,492
-17% -$1.62M 0.48% 31
2020
Q1 		$9.07M Buy
31,479
+9,604
+44% +$2.65M 0.8% 31
2019
Q4 		$6.29M Sell
21,875
-5,166
-19% -$1.12M 0.51% 62
2019
Q3 		$3.9M Sell
27,041
-984
-4% -$133K 0.27% 115
2019
Q2 		$2.52M Buy
+28,025
New +$2.25M 0.16% 166

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Atom Investors's KPTI Position: Q1 2025 in Review

Atom Investors sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 17,322 shares — an estimated $176K sold.

Atom Investors first reported a position in KPTI in Q2 2019 and held it in 12 quarters. The position peaked at $9.07M in Q1 2020. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Atom Investors reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Atom Investors sold 17,322 Karyopharm Therapeutics shares in Q1 2025, an estimated $176K.
  • Atom Investors first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 12 quarters.
  • Atom Investors's Karyopharm Therapeutics position peaked at $9.07M in Q1 2020.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Atom Investors's 13F filing for Q1 2025, filed 15 May 2025.